Tilray Inc (NASDAQ:TLRY) Shares Bought by Two Sigma Securities LLC

Two Sigma Securities LLC grew its holdings in shares of Tilray Inc (NASDAQ:TLRY) by 408.0% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 181,416 shares of the company’s stock after buying an additional 145,707 shares during the period. Two Sigma Securities LLC’s holdings in Tilray were worth $241,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also made changes to their positions in the company. Verdence Capital Advisors LLC purchased a new stake in Tilray during the fourth quarter worth approximately $29,000. Dudley Capital Management LLC acquired a new stake in Tilray during the fourth quarter worth approximately $29,000. Ameritas Advisory Services LLC purchased a new stake in shares of Tilray during the 4th quarter worth approximately $32,000. Newman Dignan & Sheerar Inc. boosted its holdings in shares of Tilray by 61.9% in the 4th quarter. Newman Dignan & Sheerar Inc. now owns 26,150 shares of the company’s stock valued at $35,000 after buying an additional 10,000 shares in the last quarter. Finally, Brooklyn FI LLC purchased a new position in shares of Tilray in the 4th quarter valued at $36,000. 9.35% of the stock is owned by institutional investors and hedge funds.

Tilray Trading Up 2.7 %

NASDAQ TLRY opened at $0.49 on Wednesday. The firm’s fifty day moving average is $0.61 and its two-hundred day moving average is $1.07. Tilray Inc has a one year low of $0.43 and a one year high of $2.52. The company has a debt-to-equity ratio of 0.10, a quick ratio of 1.58 and a current ratio of 2.54. The firm has a market cap of $492.98 million, a PE ratio of -1.63 and a beta of 1.88.

Tilray (NASDAQ:TLRY) last posted its quarterly earnings data on Tuesday, April 8th. The company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.06). Tilray had a negative net margin of 30.95% and a negative return on equity of 4.40%. The company had revenue of $185.78 million for the quarter, compared to analysts’ expectations of $213.38 million. Analysts expect that Tilray Inc will post -0.2 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the stock. Canaccord Genuity Group boosted their price target on shares of Tilray from $2.00 to $3.00 and gave the company a “buy” rating in a research report on Monday, January 13th. Piper Sandler decreased their target price on Tilray from $2.00 to $1.00 and set a “neutral” rating for the company in a research report on Wednesday, April 9th. Finally, Roth Capital reaffirmed a “neutral” rating on shares of Tilray in a research report on Monday, April 14th.

Tilray Profile

Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Canada.